Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Hum Exp Toxicol ; 33(5): 504-16, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-23690228

RESUMO

The aim of this study was to document the effect of hesperidin on the key enzyme activities of carbohydrate metabolism, lipid profile, and membrane-bound adenosine triphosphatases (ATPases) during 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast carcinogenesis. Hesperidin has been reported to have multiple biological properties. Breast cancer was induced by single dose of DMBA (20 mg/kg body weight (bw)). The results revealed that there was a significant increase in the activities of hexokinase, phosphoglucoisomerase, and aldolase and a concomitant decrease in the activities of glucose-6-phosphatase and fructose-1,6-diphosphatase in cancer-induced animals. The activities of ATPases were found to be decreased both in erythrocyte membrane and in the liver of mammary cancer-bearing animals. The lipid profiles such as total cholesterol, free cholesterol, phospholipids, triglycerides, and free fatty acids significantly increased and in contrast the ester cholesterol in plasma was found to be decreased, whereas it was found to be elevated in the liver of cancer-bearing groups. The altered levels of the above-mentioned biochemical parameters in cancer-bearing animals were significantly ameliorated by the administration of hesperidin at the dosage of 30 mg/kg bw for 45 days. The histopathological analysis of breast and liver tissues were well supported the modulatory property of hesperidin, and this might be associated with normalizing the gluconeogenesis process, stabilization of cell membranes, and modulation of lipid biosynthesis.


Assuntos
9,10-Dimetil-1,2-benzantraceno/toxicidade , Adenosina Trifosfatases/metabolismo , Metabolismo dos Carboidratos , Carcinógenos/toxicidade , Hesperidina/farmacologia , Metabolismo dos Lipídeos , Neoplasias Mamárias Experimentais/metabolismo , Animais , Membrana Celular/efeitos dos fármacos , Membrana Celular/enzimologia , Feminino , Neoplasias Mamárias Experimentais/induzido quimicamente , Neoplasias Mamárias Experimentais/enzimologia , Ratos , Ratos Sprague-Dawley
2.
Diabetes Res Clin Pract ; 77(2): 215-22, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17141354

RESUMO

The aim of the study was to compare the efficacy of insulin glargine and aspart with NPH insulin and aspart in a basal bolus regimen in type 1 diabetes. In this 36-week randomised open-label two-period cross-over trial, subjects received 16 weeks' treatment with either once-daily insulin glargine or twice-daily NPH insulin after 4-week run-in. Primary outcome was HbA1c and secondary outcomes were fasting plasma glucose (FPG), weight change, incidence of hypoglycaemia, effect on lipid profile and patient satisfaction. Sixty patients with type 1 diabetes were recruited (33 male, mean age 42.7 years, mean HbA1c 8.53%) with 53 completing the study. At completion, HbA1c was lower with glargine and aspart than with NPH and aspart (8.07% versus 8.26%, difference -0.19 [95% CI 0.37-0.01]%, p=0.04). FPG was significantly different between glargine and NPH (p=0.002), with mean FPG on glargine 3mmol/L lower than on NPH at the end of the study. There were no differences in hypoglycaemia rate (p=0.63), weight (p=0.45) or lipid profile (p=0.18). Patient satisfaction was greater with glargine (DTSQ, p=0.001). Three patients discontinued as they wished to remain on glargine. We suggest that glargine combined with aspart is an effective basal bolus regimen in type 1 diabetes.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 1/tratamento farmacológico , Insulina Isófana/uso terapêutico , Insulina/análogos & derivados , Adulto , Glicemia/efeitos dos fármacos , Pressão Sanguínea , Colesterol/sangue , Estudos Cross-Over , Diabetes Mellitus Tipo 1/sangue , Esquema de Medicação , Quimioterapia Combinada , Feminino , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/administração & dosagem , Insulina/uso terapêutico , Insulina Aspart , Insulina Glargina , Insulina Isófana/administração & dosagem , Insulina de Ação Prolongada , Masculino , Pessoa de Meia-Idade
3.
J Assoc Physicians India ; 51: 175-7, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12725262

RESUMO

OBJECTIVE: To determine the prevalence of renal artery disease and to correlate the underlying risk factors like age, sex, diabetes, hypertension, urea and creatinine in patients who have undergone angiogram for cardiovascular diseases. METHODS: Retrospective analysis of the reports of angiogram of patients who have undergone cardiac catheterization in Vijaya Heart Foundation for cardiovascular diseases. RESULTS: The prevalence of renovascular stenosis is 12.4%. Prevalence of hypertension and diabetes in the group of patients with renovascular stenosis compared with group having coronary artery disease is not statistically significant (p > 0.8). Univariate and multivariate logistic identified age, diabetes, hypertension and urea as independent predicators of renal artery stenosis; while variables like sex and serum creatinine were not associated. CONCLUSION: High prevalence of unsuspected renovascular abnormalities is found in patients who undergo angiography for cardiovascular disease. Factors like age, diabetes, hypertension and urea could be clinical predicators of renal artery stenosis. Hence renal arteries should be visualized routinely in patients undergoing coronary angiogram for cardiovascular disease.


Assuntos
Cateterismo Cardíaco , Doenças Cardiovasculares/epidemiologia , Nefropatias/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/diagnóstico , Feminino , Humanos , Índia/epidemiologia , Nefropatias/diagnóstico , Nefropatias/etiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores de Risco
4.
Nephron ; 92(4): 929-30, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12399642

RESUMO

We report a patient with tetralogy of Fallot who developed spontaneous bilateral perirenal hematoma at the age of 35. Polycythemia was seen from the age of 3 in this patient. Prolonged clotting time and partial thromboplastin time were observed on various occasions before he developed perirenal hematoma. Blood letting was done periodically according to the value of hemoglobin level and packed cell volume. Resolution of hematoma was seen sonographically.


Assuntos
Hematoma/complicações , Rim/patologia , Tetralogia de Fallot/complicações , Adulto , Hematoma/patologia , Humanos , Rim/diagnóstico por imagem , Masculino , Policitemia , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...